Article
Author(s):
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
Staying the course in shifting winds
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
FDA approves expanded label for fluocinolone acetonide intravitreal implant
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Case report: Bilateral retinal detachments in a 19-year-old
ARVO announces recipients of the 2025 ARVO Foundation Early Career Clinician-Scientist Awards